Impact of a Cardiac Rehabilitation Program on Patients With Cardiac Amyloidosis

The goal of this clinical trial is to learn if a structured cardiac rehabilitation program can help people with cardiac amyloidosis improve their ability to exercise and their quality of life. The main questions it aims to answer are: Does cardiac rehabilitation raise peak oxygen uptake (VO₂ peak), which shows how well the heart and lungs work during exercise? Is cardiac rehabilitation safe and practical for people with cardiac amyloidosis? How does cardiac rehabilitation affect other exercise measures, heart function, symptoms linked to autonomic dysfunction, and quality of life? This study has no comparison group. Researchers will measure each participant's results before and after the rehabilitation program. Participants will: Complete a cardiac rehabilitation program for 5 weeks. Have tests before the program starts and again about 3 months later. These tests include: A cardiopulmonary exercise test A heart function test using electrical impedance A questionnaire about quality of life A blood sample A blood pressure test to check for orthostatic hypotension The study will include adults aged 18 or older with transthyretin cardiac amyloidosis who are able to perform an exercise test.

NCT Number	NCT07494942
Lead Sponsor	University Hospital, Montpellier
Conditions	Amyloidosis
Enrollment	40 participants
Start Date	2026-04-30
Primary Completion	2029-01-30 (estimated)
Study Completion	2029-01-30 (estimated)
Updated on ClinicalTrials.gov	2026-04-01